Cargando…

Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21)

Acute myeloid leukemia (AML) is a major blood cancer with poor prognosis. New therapies are needed to target oncogene-driven leukemia stem cells, which account for relapse and resistance. Chromosome translocation t(8;21), which produces RUNX1-ETO (R-E) fusion oncoprotein, is found in ~13% AML. R-E d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Lianghao, Wen, Yefei, Yao, Yuan, Chen, Fengju, Wang, Guohui, Wu, Fangrui, Wu, Jingyu, Narayanan, Padmini, Redell, Michele, Mo, Qianxing, Song, Yongcheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928880/ https://www.ncbi.nlm.nih.gov/pubmed/29721072 http://dx.doi.org/10.7150/thno.22800

Ejemplares similares

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia
por: Issa, Hasan, et al.
Publicado: (2023)

RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML
por: Loke, Justin, et al.
Publicado: (2017)

The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling
por: Stoner, Samuel A., et al.
Publicado: (2020)

Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding
por: Ptasinska, A, et al.
Publicado: (2012)

RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction
por: Ptasinska, Anetta, et al.
Publicado: (2019)

RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction
por: Ptasinska, Anetta, et al.
Publicado: (2019)

Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
por: Feng, Zizhen, et al.
Publicado: (2016)

MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR
por: Johnson, Daniel T., et al.
Publicado: (2021)

The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation
por: Martinez-Soria, Natalia, et al.
Publicado: (2018)

The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation
por: Martinez-Soria, Natalia, et al.
Publicado: (2019)

RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner
por: Abdallah, Mohamed Gaber, et al.
Publicado: (2021)

Successful Outcome of a Case of Acute Myeloid Leukemia with t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis
por: Meng, Guangqiang, et al.
Publicado: (2019)

Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement
por: Tokunaga, Kenji, et al.
Publicado: (2017)

Targeting miR‐193a‐AML1‐ETO‐β‐catenin axis by melatonin suppresses the self‐renewal of leukaemia stem cells in leukaemia with t (8;21) translocation
por: Zhou, Bin, et al.
Publicado: (2019)

RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia
por: van der Kouwe, Emiel, et al.
Publicado: (2019)

Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO/C-KIT Oncoprotein in t(8;21) Leukemia
por: Yu, Xianjun, et al.
Publicado: (2016)

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
por: Agrawal, Mridul, et al.
Publicado: (2019)

Thermodynamic investigation of DNA-binding affinity of wild-type and mutant transcription factor RUNX1
por: Wu, Fangrui, et al.
Publicado: (2019)

MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO
por: Kohrs, Nicole, et al.
Publicado: (2016)

The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype
por: Forster, V J, et al.
Publicado: (2016)

The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells
por: Martinez, Natalia, et al.
Publicado: (2004)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia
por: Purev, Enkhtsetseg, et al.
Publicado: (2014)

ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
por: Hartmann, Luise, et al.
Publicado: (2016)

Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells
por: Trombly, Daniel J, et al.
Publicado: (2015)

A novel epigenetic AML1‐ETO/THAP10/miR‐383 mini‐circuitry contributes to t(8;21) leukaemogenesis
por: Li, Yonghui, et al.
Publicado: (2017)

Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells
por: Nafria, Monica, et al.
Publicado: (2020)

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein
por: Cao, Jiang, et al.
Publicado: (2016)

A Novel KIT INDEL Mutation in Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
por: Lee, Jun Hyung, et al.
Publicado: (2016)

RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1
por: Ponnusamy, K, et al.
Publicado: (2015)

RUNX1 and its fusion oncoprotein derivative RUNX1-ETO induce senescence-like growth arrest independently of replicative stress
por: Wolyniec, Kamil, et al.
Publicado: (2009)

Chidamide inhibits t(8;21) AML cell proliferation and AMK1/ETO and C-KIT expression by inhibiting ERK1/2 signaling pathway
por: Liu, Jing, et al.
Publicado: (2020)

Restoration of MYC-repressed targets mediates the negative effects of GM-CSF on RUNX1-ETO leukemogenicity
por: Weng, Stephanie, et al.
Publicado: (2016)

Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives
por: Song, Yongcheng, et al.
Publicado: (2016)

Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors
por: Wichmann, C, et al.
Publicado: (2015)

Images from the Haematologica Atlas of Hematologic Cytology: acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
por: Invernizzi, Rosangela
Publicado: (2022)

Interference with RUNX1/ETO Leukemogenic Function by Cell-Penetrating Peptides Targeting the NHR2 Oligomerization Domain
por: Bartel, Yvonne, et al.
Publicado: (2013)

Biophysical and pharmacokinetic characterization of a small-molecule inhibitor of RUNX1/ETO tetramerization with anti-leukemic effects
por: Gopalswamy, Mohanraj, et al.
Publicado: (2022)

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2017)

Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1
por: Zhou, Chao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jnflrvppmakv5bo502f3aj3ba9